Skip to main content

Table 3 Dosimetric comparison of two IMRT techniques

From: A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events

Target / Organ at risk

Average dose (Mean ± SD, Gy)

p-value

SEQ

SIB

PTV-HR dose (D95%)

69.80 ± 2.66

69.47 ± 2.00

0.452

PTV-LR dose (D95%)

52.21 ± 3.22

56.71 ± 2.07

0.000

Maximal spinal cord dose (D1cc)

40.65 ± 4.34

42.09 ± 2.23

0.030

Maximal brain stem dose (D1cc)

48.84 ± 6.02

50.13 ± 4.44

0.193

Median dose of one parotid gland (D50%)a

24.44 ± 8.69

21.91 ± 4.04

0.035

Maximal optic nerve dose

30.06 ± 13.99

34.26 ± 16.58

0.132

Median cochlear dose (D50%)

47.26 ± 8.52

44.01 ± 7.84

0.032

Maximal eye dose

19.40 ± 7.34

23.05 ± 9.10

0.016

Maximal lens dose

6.44 ± 1.78

7.91 ± 1.07

0.149

Maximal mandible dose

71.27 ± 5.22

71.02 ± 5.74

0.802

Median oral cavity dose (D50%)

37.28 ± 4.21

36.40 ± 4.30

0.256

Median vocal cord dose (D50%)

39.55 ± 6.16

40.97 ± 4.85

0.667

  1. aThe smallest dose between bilateral parotid glands